Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ALX Oncology
Biotech
Metsera sale architect swings to Structure—Chutes & Ladders
Metsera acquisition architect swings to Structure. Vir CMO exits after less than 2 years. Leal reels in Big Pharma vets to exec team.
Darren Incorvaia
,
Zoey Becker
,
Will Maddox
Apr 17, 2026 10:10am
CatalYm catalyzes C-suite shake-up—Chutes & Ladders
Sep 19, 2025 8:30am
Pfizer vet lands first CEO role—Chutes & Ladders
Aug 15, 2025 8:30am
ALX Oncology doubles down as lead asset fails 2 phase 2 trials
Apr 25, 2025 2:25pm
ALX lays off 30% of staff to pay for more trials of CD47 blocker
Mar 5, 2025 9:40am
Flagship-backed biotechs name new leaders—Chutes & Ladders
Nov 15, 2024 8:30am